Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for secondary hyperparathyroidism in hemodialysis patients
IRCT20251127068128N1Phase 3Recruiting
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of melatonin in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoint: Parathyroid hormone level change. Started Nov 2025; status: recruiting.
02
Drugs
melatonin
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20251127068128N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251127068128N1.